Aleglitazar
Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator ) with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes.[1] It is no longer in phase III clinical trials.[2]
Names | |
---|---|
IUPAC name
(2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-7-benzothiophenyl]propanoic acid | |
Other names
Ro-0728804, R-1439 | |
Identifiers | |
3D model (JSmol) |
|
ChEMBL | |
ChemSpider | |
DrugBank | |
ECHA InfoCard | 100.220.523 |
KEGG | |
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
Properties | |
C24H23NO5S | |
Molar mass | 437.51 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
References
- "Statement on a nonproprietary name adopted by the USAN Council: Aleglitazar" (PDF). United States Adopted Names. American Medical Association. Retrieved 2008-08-17.
- "Roche halts diabetes drug trial in blow to pipeline". Roche. 2013-07-10. Retrieved 2013-07-10.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.